title: Usefulness of detection of complement activation products in evaluating SLE activity.
abstract: Complement activation products, such as C1rs-C1inh, specific for the activation of the classical pathway, C3b(Bb)P, specific for the activation of the alternative pathway and SC5b-9, specific for common terminal pathway of the complement cascade, were measured in healthy donors and in patients with clinically active and inactive systemic lupus erythematosus (SLE). Plasma levels of C3b(Bb)P and SC5b-9 were moderately, those of C1rs-C1inhibitor (C1rs-C1inh) were markedly elevated in patients with clinically inactive SLE, compared with healthy controls. The difference between active and inactive stages of the disease was best reflected by C3b(Bb)P plasma concentration (P<0.001), which also showed the highest correlation with the SLEDAI (Rs=0.41 P<0.001) and which was the most useful in distinguishing active and inactive sample pairs as well. The difference between SC5b-9 levels in the active and inactive stages was also significant (P=0.007), while that of C1rs-C1inh did not differ significantly (P=0.136). The correlation of the SLEDAI with SC5b-9 was 0.3 (P=0.015), while with C1rs-C1inh it was 0.21 (P=0. 089). These findings suggest that the measurement of complement activation products, especially that of the alternative pathway, are sensitive markers of the activity of SLE and can be used for clinical purposes.
authors.affiliation: Central Laboratory of Immunology, Semmelweis University of Medicine, Budapest, Hungary.
authors.forename: G
authors.initials: G
authors.lastname: Nagy
authors.forename: M
authors.initials: M
authors.lastname: Brózik
authors.forename: L
authors.initials: L
authors.lastname: Varga
authors.forename: G
authors.initials: G
authors.lastname: Füst
authors.forename: M
authors.initials: M
authors.lastname: Kirschfink
authors.forename: E
authors.initials: E
authors.lastname: Kiss
authors.forename: P
authors.initials: P
authors.lastname: Gergely
mesh_terms: D000328:Adult; D003167:Complement Activation; D003174:Complement C1 Inactivator Proteins / Q000032:analysis*; D015923:Complement C1r / Q000032:analysis*; D051561:Complement C3 Convertase, Alternative Pathway; D003179:Complement C3b / Q000032:analysis*; D015938:Complement Membrane Attack Complex; D003165:Complement System Proteins / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006023:Glycoproteins / Q000032:analysis*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000032:analysis*; D012680:Sensitivity and Specificity
chemical_list: D003174:Complement C1 Inactivator Proteins; D015938:Complement Membrane Attack Complex; D006023:Glycoproteins; D010446:Peptide Fragments; C047610:SC5b-9 protein complex; D003179:Complement C3b; D003165:Complement System Proteins; D015923:Complement C1r; D051561:Complement C3 Convertase, Alternative Pathway